Europe/Asia USA
Bachem AG Bachem Americas, Inc.
Hauptstrasse 144 3132 Kashiwa Street
4416 Bubendorf - Switzerland Torrance, CA 90505 - USA
Tel +41 61 935 2323 Tel +1 888 422 2436
Fax +41 61 935 2325 +1 888 4BACHEM
E-mail +1 310 539 4171
  Fax +1 310 539 9428



09. May 2007
Neuren and Bachem continue close collaboration on Glypromate® - Neuren’s lead product now in phase III

Bachem and Neuren Pharmaceuticals Limited today announced to continue their close collaboration on Glypromate®, Neuren’s lead product currently under development for the prevention of cognitive impairment following major cardiac surgery. During the long-standing partnership from pre-clinical development up to today, Bachem has provided Neuren the active ingredient and complete regulatory documentation on its GMP production. Recently the US American regulatory agency, FDA, has approved Neuren’s investigational drug application (IND) and authorized the company to proceed with a phase III trial on Glypromate®. This decision brings the partnership between Bachem and Neuren into a new dimension. The phase III clinical trial requires substantial higher quantities of the developmental compound and initial preparation for securing supply for a potential market launch, which is actually planned for 2010.


Press Release